Zofran and Neoplasm malignant - a phase IV clinical study of FDA data

Summary:

Neoplasm malignant is reported as a side effect among people who take Zofran (ondansetron hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Zometa, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Neoplasm malignant when taking Zofran. It is created by eHealthMe based on reports of 93,713 people who have side effects when taking Zofran from the FDA, and is updated regularly.

What is Zofran?

Zofran has active ingredients of ondansetron hydrochloride. It is often used in nausea. eHealthMe is studying from 94,987 Zofran users. Check the latest studies of Zofran.

What is Neoplasm malignant?

Neoplasm malignant (cancer tumour) is found to be associated with 1,537 drugs and 1,261 conditions by eHealthMe. Check the latest studies of Neoplasm malignant.

On Jul, 11, 2026

93,713 people reported to have side effects when taking Zofran.
Among them, 571 people (0.61%) have Neoplasm malignant.

Among these 571 people:

* Approximation only. Some reports may have incomplete information.

Do you take Zofran and have Neoplasm malignant?

- Check whether Neoplasm malignant is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zofran:

Zofran (94,987 reports)

Neoplasm malignant treatments and more:

Neoplasm malignant (105,565 reports)

How severe was Neoplasm malignant and when was it recovered:

Neoplasm malignant in Zofran

Expand to all the drugs that have ingredients of ondansetron hydrochloride:

Neoplasm malignant and drugs with ingredients of ondansetron hydrochloride (556 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zofran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm malignant:

Neoplasm malignant (1,537 drugs)

Browse all the conditions that are associated with Neoplasm malignant:

Neoplasm malignant (1,261 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron hydrochloride (the active ingredients of Zofran) and Zofran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.